AP
MRNA icon

AtonRa Partners’s Moderna MRNA Stock Holding History

AtonRa Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$243K Sell
2,446
-271
-10% -$22.8K 0.48% 96
2023
Q3 		$281K Sell
2,717
-570
-17% -$63.6K 0.59% 83
2023
Q2 		$399K Sell
3,287
-118
-3% -$15.7K 0.62% 76
2023
Q1 		$523K Sell
3,405
-341
-9% -$56.3K 0.76% 55
2022
Q4 		$673K Sell
3,746
-1,013
-21% -$166K 0.86% 52
2022
Q3 		$563K Sell
4,759
-142
-3% -$21.5K 0.55% 81
2022
Q2 		$700K Sell
4,901
-4,355
-47% -$622K 0.64% 69
2022
Q1 		$1.59M Sell
9,256
-4,482
-33% -$755K 0.87% 44
2021
Q4 		$3.49M Buy
13,738
+69
+0.5% +$20.2K 1.21% 28
2021
Q3 		$5.26M Sell
13,669
-1,905
-12% -$703K 1.76% 10
2021
Q2 		$3.66M Sell
15,574
-9,180
-37% -$1.64M 1.34% 22
2021
Q1 		$3.24M Buy
24,754
+2,194
+10% +$318K 1.45% 14
2020
Q4 		$2.36M Buy
+22,560
New +$2.28M 1.16% 37

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AtonRa Partners's MRNA Position: Q4 2023 in Review

AtonRa Partners reduced its Moderna (MRNA) stake by 10% in Q4 2023, selling an estimated $22.8K and leaving 2,446 shares worth $243K. The position accounts for 0.48% of the portfolio, ranked #96.

AtonRa Partners first reported a position in MRNA in Q4 2020 and has held it in 13 quarters since. The position peaked at $5.26M in Q3 2021. 884 funds tracked by Wall St. Rank hold MRNA as of Q4 2023.

  • AtonRa Partners held 2,446 shares of Moderna worth $243K as of Q4 2023.
  • AtonRa Partners sold 271 Moderna shares in Q4 2023, an estimated $22.8K.
  • Moderna made up 0.48% of AtonRa Partners's portfolio in Q4 2023, its #96 holding.
  • AtonRa Partners first reported a position in Moderna in Q4 2020 and has held it in 13 quarters since.
  • AtonRa Partners's Moderna position peaked at $5.26M in Q3 2021.
  • 884 funds tracked by Wall St. Rank held Moderna as of Q4 2023.

Based on AtonRa Partners's 13F filing for Q4 2023, filed 5 Feb 2024.